Logo

Gene Logic Closes TherImmune Research Acquisition

Apr 02, 2003

NEW YORK, April 2 - Gene Logic of Gaithersburg, Md., today announced the completion of its $52 million acquisition of TherImmune Research.

 

Gene Logic paid TherImmune shareholders approximately $30.9 million in cash, and issued 4 million shares of common stock, with a value of approximately $21.2 million, based on the closing price of its stock

 

The company announced the acquisition in February.         

Breaking News
The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.